|
|
|
|
||
my end of year review of LCTXINTRO Here's my semi-annual exercise to see if I remember why I own the stocks I own, and so I can check back and see if their stories have changed. I post in case it helps others too. Lineage Cell Therapeutics LCTX (market cap is $0.413B was $0.462B) Lineage Cell Therapeutics is a relatively small biotech hoping to implement treatments for macular degeneration, damaged spinal cords, and other ailments. The macular degeneration and spinal cord work rely on stem cell developments, which is the origin for how I became interested in the company. Stem cell treatments are innovative enough that the FDA may be extra-rigorous (and hence slow) in approving the treatments. Such treatments also meet unmet needs, which may prompt popular pressure for earlier, rather than later, approval. Clinical trials are proceeding well enough to be encouraging. They are necessarily small-scale studies, but some of the patients are experiencing improved eyesight and some are regaining motor function as appropriate to each study. The company suggests (forward looking statements, etc.) that approval and commercial production may be only a few years away. Paraphrasing the company, the market for spinal cord treatments is estimated to be at least $3B, and the market for treating macular degeneration is estimated to be at least $12B, both by 2026. As with most innovative biotechs, the risks are high, the need may be great, and the rewards can also be significant. If the treatments fail, however, then the downside of the risk can become apparent quickly. DISCLOSURE LTBH by habit, but having to remember that my LCTX/BTX holdings came from AST (2014) which was spun off from GERN (which I’ve held since 1999). I hear patience pays, but it is easy to have doubts after twenty years of waiting. (I've also collected links to the other discussion boards and my other stocks over on my blog https://trimbathcreative.net/2021/12/31/semi-annual-exercise-eoy-2021/ ) |
return to message board, top of board |